| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Net sales | 425,864 | 503,612 | 510,353 | |
| Cost of sales | 171,401 | 200,954 | 240,530 | |
| Gross profit | 254,463 | 302,658 | 269,823 | |
| Selling and marketing | 358,535 | 345,505 | 280,549 | |
| Research and development | 227,993 | 228,606 | 196,912 | |
| General and administrative | 1,122,684 | 1,564,967 | 1,275,161 | |
| Depreciation and amortization of intangible assets | 16,268 | 22,184 | 23,952 | |
| Total operating expenses | 1,725,480 | 2,161,262 | 1,776,574 | |
| Loss from operations | -1,471,017 | -1,858,604 | -1,506,751 | |
| Other income | 7,299 | 4,357 | 5,877 | |
| Interest expense | 5,059 | 2,561 | 4,993 | |
| Change in fair value of earnout liabilities | -86,104 | 29,630 | - | |
| Inventory write-down | 47,082 | - | - | |
| Amortization of debt discount | 0 | 0 | - | |
| Loss on forward purchase agreement | 0 | 0 | - | |
| Loss on lease termination | 0 | - | - | |
| Total other income (expense) | 41,262 | -27,834 | 884 | |
| Loss from continuing operations before income taxes | -1,429,755 | -1,886,438 | -1,505,867 | |
| Income tax benefit | 0 | 0 | - | |
| Loss from continuing operations | -1,429,755 | -1,886,438 | -1,505,867 | |
| Loss from discontinued operations | 0 | 0 | - | |
| Gain on sale of discontinued operations | 0 | 0 | - | |
| Net loss | -1,429,755 | -1,886,438 | -1,505,867 | |
| Basic net income (loss) per share | -0.83 | -1.56 | -1.52 | |
| Diluted net income (loss) per share | -0.83 | -1.56 | -1.52 | |
| Weighted average shares outstanding, basic | 1,723,434 | 1,209,809 | 991,210 | |
| Weighted average shares outstanding, diluted | 1,723,434 | 1,209,809 | 991,210 | |
Longevity Health Holdings, Inc. (XAGE)
Longevity Health Holdings, Inc. (XAGE)